You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
None
Lymphoma is a group of malignant diseases caused by the clonal proliferation of lymphocytes. Current treatment options include chemotherapy, radiotherapy, and bone marrow/stem cell transplantation. Development of new treatment options for cancer medications include small molecules and monoclonal antibodies for immunotherapy. In addition, the discovery of new phytochemical agents used in complementary and alternative medicine adds perspective to the treatment of lymphoma. This book highlights recent developments in the treatment of lymphoma. Chapters discuss different types of lymphomas, such as follicular lymphoma, gastrointestinal lymphoma, splenic B-cell lymphoma, and others, as well as the available treatment options for each.
This chapter aims to provide a complete knowledge over the primary intraocular lymphoma (PIOL) and a correct clinical approach towards this rare condition, to avoid delays in diagnosis, which is considered the most important prognostic factor. A PIOL arises with no specific symptoms and could mimic both inflammatory and non-inflammatory ocular conditions. Also known as reticulum cell sarcoma in the past, PIOL is an ocular malignant condition, with a strong bond with primary central system lymphoma (PCNSL). This linkage is underlined by the fact that approximately 30% of the patients with PIOL have also PCNSL at presentation, while 45,Äì90% will develop PCSNL in the following months. A correct diagnosis is currently achieved by the means of many different techniques: cytology, flow cytometry, immunohistochemistry, molecular analysis, and cytokines assay. Treatment of this condition has been completely revolutionized with the introduction of monoclonal antibodies directed against specific proteins present on the surface of lymphomatous cells.
This book deals with the emergence of intellectual monopolies. It explores different ways of producing knowledge, thus showing alternatives to the current dominant paradigm which is based on turning knowledge produced collectively into intangible assets, owned by a few leading corporations. It discusses a paradox: knowledge creation by government-sponsored research infrastructures (RI) or by non-profit institutions, including universities, is increasingly appearing in the form of "open science" - ideas and data are widely available in the public domain. However, such knowledge is privatised downstream by new oligopolies. These oligopolies, such as the Tech Giants, are protected by legislatio...
None